# Comet Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/comet-therapeutics

- Industry: Biopolymers
- Headquarters: Cambridge, US
- Website: www.comettherapeutics.com
- Total disclosed funding: $14M
- Latest round: Series A (Jun 6, 2019)
- Investors on record: 4

## About

Comet Therapeutics, Inc. is a biopharmaceutical company focusing on developing innovative therapies for chronic diseases, particularly autoimmune disorders and metabolic diseases, to address significant unmet medical needs.Founded in 2017 and headquartered in Cambridge, US, Comet Therapeutics, Inc. specializes in creating therapeutics targeting specific biological pathways. The company has completed three deals to date, with its latest funding round being a Series A, raising USD 14.05 mn from investors including Canaan Partners and Sofinnova Partners.Comet Therapeutics specializes in developing innovative therapeutics aimed at addressing unmet medical needs in various therapeutic areas. The company’s core product offerings include advanced biopharmaceuticals designed to target specific biological pathways implicated in chronic diseases, particularly focusing on autoimmune disorders and metabolic diseases. Comet Therapeutics serves a diverse client base, including healthcare providers, research institutions, and pharmaceutical companies in North America and Europe, emphasizing collaborative partnerships to facilitate the clinical development and commercialization of its products.Comet Therapeutics generates revenue through strategic partnerships and collaborations with other pharmaceutical entities, along with direct sales of its proprietary therapeutics. Revenue streams typically involve licensing agreements with upfront fees and royalties on future sales, supported by structured pricing plans that may include tiered subscription models or one-time transaction fees for access to specific therapies.The most recent deal, finalized on August 31, 2021, involved the acquisition of Comet Therapeutics, Inc. by Vectivbio AG, which aims to enhance its rare disease pipeline. With the support of recent funding, Comet Therapeutics plans to expand its therapeutic offerings and explore new geographic markets, particularly in Europe and Asia, to further address unmet medical needs in those regions.

## Funding rounds

- Series A, Jun 6, 2019, $14M — Sofinnova Partners, Canaan Partners, Inkef, Mission Biocapital
- Seed, Jun 1, 2017 — Sofinnova Partners, Inkef

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A
- Inkef (https://capitalatlas.ai/funds/inkef) — Seed, Series A
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series A